Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide
© 2024 Wiley Periodicals LLC..
The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) has been associated with improved disease-free survival. These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin-2 (IL-2). This monocentric phase I, open-label, dose-escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T-cells early after h-HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low-doses of IL-2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T-cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h-HSCT recipients. Twenty-six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h-HSCT only. At the three dose levels tested, 1, 0, and 1 dose-limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T-cells was observed during IL-2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T-cells is feasible after h-HSCT by using a combination of ZA and repeated IL-2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
American journal of hematology - 99(2024), 3 vom: 12. Feb., Seite 350-359 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jullien, Maxime [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6XC1PAD3KF |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT03862833 Citation Status MEDLINE |
|---|
| doi: |
10.1002/ajh.27191 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366556541 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366556541 | ||
| 003 | DE-627 | ||
| 005 | 20240214233043.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ajh.27191 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM366556541 | ||
| 035 | |a (NLM)38165016 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jullien, Maxime |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03862833 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a The presence of donor Vγ9Vδ2 T-cells after haploidentical hematopoietic stem cell transplant (h-HSCT) has been associated with improved disease-free survival. These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in combination with interleukin-2 (IL-2). This monocentric phase I, open-label, dose-escalating study (ClinicalTrials.gov: NCT03862833) aimed at evaluating the safety and possibility to generate Vγ9Vδ2 T-cells early after h-HSCT. It applied a standard 3 + 3 protocol to determine the maximum tolerated dose (MTD) of increasing low-doses of IL-2 (5 days [d] per week, 4 weeks) in combination with a single dose of ZA, starting both the first Monday after d + 15 posttransplant. Vγ9Vδ2 T-cell monitoring was performed by multiparameter flow cytometry on blood samples and compared with a control cohort of h-HSCT recipients. Twenty-six patients were included between April 2019 and September 2022, 16 of whom being ultimately treated and seven being controls who received h-HSCT only. At the three dose levels tested, 1, 0, and 1 dose-limiting toxicities were observed. MTD was not reached. A significantly higher number of Vγ9Vδ2 T-cells was observed during IL-2 treatment compared with controls. In conclusion, early in vivo generation of Vγ9Vδ2 T-cells is feasible after h-HSCT by using a combination of ZA and repeated IL-2 infusions. This study paves the way to a future phase 2 study, with the hope to document lesser posttransplant relapse with this particular adaptive immunotherapy | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Zoledronic Acid |2 NLM | |
| 650 | 7 | |a 6XC1PAD3KF |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Guillaume, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Le Bourgeois, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Peterlin, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Garnier, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Eveillard, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Le Bris, Yannick |e verfasserin |4 aut | |
| 700 | 1 | |a Bouzy, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Tessoulin, Benoît |e verfasserin |4 aut | |
| 700 | 1 | |a Gastinne, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Dubruille, Viviane |e verfasserin |4 aut | |
| 700 | 1 | |a Touzeau, Cyrille |e verfasserin |4 aut | |
| 700 | 1 | |a Mahé, Béatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Blin, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Vantyghem, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Sortais, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Antier, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Scotet, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Béné, Marie C |e verfasserin |4 aut | |
| 700 | 1 | |a Chevallier, Patrice |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of hematology |d 1993 |g 99(2024), 3 vom: 12. Feb., Seite 350-359 |w (DE-627)NLM000124354 |x 1096-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2024 |g number:3 |g day:12 |g month:02 |g pages:350-359 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ajh.27191 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2024 |e 3 |b 12 |c 02 |h 350-359 | ||